Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.
Jessica Chang, MA
Advertisement
Articles by Jessica Chang, MA
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.
Advertisement
Latest Updated Articles
- Site of Care Potentially Limits Cost Savings From Biosimilars
August 23rd 2021
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5